Send the following on WhatsApp
Continue to ChatI liked this article on M3 India: Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: Results from an open‐label phase IIa study and subsequent phase III open‐label extension study. Have a read: https://www.m3india.in/contents/journal/dupilumab-provides-favourable-long-8208-term?utm_campaign=unset&utm_medium=share&utm_source=ref_wa